Dmitri Ossipov

Dr. Dmitri Ossipov

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2006 in Macromolecules
Verified
Journal Article
Closed access
Dmitri OssipovDmitri Ossipov
Dmitri Ossipov
JHJons Hilborn
Jons Hilborn

23 January 2019 in Macromolecular Rapid Communications
Verified
Journal Article
Closed access
PDF file
Liyang ShiLiyang Shi
Liyang Shi
PDPinghui Ding
Pinghui Ding
YWYuzhi Wang
Yuzhi Wang
YZYu Zhang
Yu Zhang
Dmitri OssipovDmitri Ossipov
Dmitri Ossipov
JHJons Hilborn
Jons Hilborn

2 August 2017 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
Liyang ShiLiyang Shi
Liyang Shi
FWFanlu Wang
Fanlu Wang
WZWei Zhu
Wei Zhu
ZXZongpu Xu
Zongpu Xu
SFSabine Fuchs
Sabine Fuchs
Dmitri OssipovDmitri Ossipov
Dmitri Ossipov

1 June 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
Elena Martinez-SanzElena Martinez-Sanz
Elena Martinez-Sanz
Dmitri OssipovDmitri Ossipov
Dmitri Ossipov
JHJons Hilborn
Jons Hilborn
SLSune Larsson
Sune Larsson
KJKenneth B. Jonsson
Kenneth B. Jonsson
OVOommen Varghese
Oommen Varghese

5 April 2010 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Dmitri OssipovDmitri Ossipov
Dmitri Ossipov
Active targeting of bioactive molecules by physicochemical association with hyaluronic acid (HA) is an attractive approach in current nanomedicine because HA is biocompatible, non-toxic and non-inflammatory. This review focuses on synthesis, physicochemical characterization and biological properties of different nanoparticulate delivery systems that include HA in their structures. Chemically based approaches to the delivery of small molecule drugs, proteins and nucleic acids in which they become chemically or physically bound to hyaluronic acid are reviewed, including the use of molecular HA conjugates and nanocarriers. The systems are considered in terms of intracellular delivery to different cultured cells that express HA-specific receptors (hyaladherines) differently. The in vivo biodistribution and therapeutic effect of these systems are discussed. Different synthetic methodologies for preparations of HA-based nanoparticles are presented extensively. HA nanoparticulate systems of various structures can be compared with respect to their in vitro assays and in vivo biodistribution. To make HA useful as an intravenous targeting carrier, strategies have to be devised to: reduce HA clearance from the blood; suppress the HA uptake by liver and spleen; and provide tumor-triggered mechanisms of release of an active drug from the HA carrier.

27 December 2017 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
Liyang ShiLiyang Shi
Liyang Shi
YZYannan Zhao
Yannan Zhao
QXQifan Xie
Qifan Xie
CFCaixia Fan
Caixia Fan
JHJöns Hilborn
Jöns Hilborn
Dmitri OssipovDmitri Ossipov
Dmitri Ossipov